The term "EPFL7 Antibody" can refer to different molecules depending on the context. Recent research highlights an antibody called P2G3, discovered by scientists at Lausanne University Hospital (CHUV) and EPFL, that effectively neutralizes SARS-CoV-2 variants, including Omicron sub-variants . Additionally, "EGFL7 antibody" (Epidermal Growth Factor-Like protein 7 antibody) is a commercially available antibody targeting the EGFL7 protein, which is involved in vascular tubulogenesis . Another research direction involves Epidermal Growth Factor Receptor (EGFR) inhibitors, with studies focusing on identifying and developing molecules that can overcome drug resistance in cancer treatments .
P2G3 is a monoclonal antibody that exhibits potent neutralizing activity against all SARS-CoV-2 variants of concern, including Omicron sub-variants . It was isolated from a donor previously infected and vaccinated twice . The antibody functions by binding to a specific region of the Spike protein, preventing the virus from binding to the ACE2 receptor on cells targeted by the infection .
P2G3's mechanism of action involves binding to a conserved region of the Spike protein, which inhibits the virus's ability to attach to the ACE2 receptor on host cells . This interaction halts the viral replication process, allowing the patient’s immune system to clear SARS-CoV-2 from the body .
Structural studies indicate that P2G3 and P5C3, another broad-spectrum antibody, bind to distinct sites on the Spike protein, demonstrating their complementarity . This complementarity means that P2G3 neutralizes mutants that escape P5C3, and vice versa .
Prophylactic Use When used prophylactically, P2G3 provides complete protection against Omicron BA.1 variant infection in primates .
Therapeutic Use In combination with P5C3, P2G3 is highly effective in blocking virus multiplication in already infected animals .
Clinical trials to confirm the neutralizing activity of P2G3 against Omicron BA.4 and BA.5 variants began in August 2022 .
The Anti-EGFL7 antibody [EPR22603-113] (ab256451) is a Rabbit Recombinant Monoclonal Antibody that targets human Epidermal Growth Factor-Like protein 7 (EGFL7) . It is suitable for various applications, including WB (Western Blot), ICC/IF (Immunocytochemistry/Immunofluorescence), and IHC-P (Immunohistochemistry – Paraffin-embedded sections) .
EGFL7 regulates vascular tubulogenesis in vivo, inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration, and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis .
| Property | Description |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Isotype | IgG |
| Applications | WB, ICC/IF, IHC-P |
| Reactivity | Human |
| Buffer | PBS, 40% Glycerol, 0.05% BSA |
| Storage | +4°C for short term, -20°C for long term (aliquot) |
Research has focused on developing third-generation EGFR inhibitors to overcome resistance issues . One approach involves analyzing EGFR protein crystal complexes to identify potent inhibitors .
EPFL7 is a member of the epidermal patterning factor-like family in Arabidopsis thaliana (Mouse-ear cress). This protein is part of the signaling peptide family involved in developmental regulation pathways. As a research target, EPFL7 requires specific antibody-based detection methods due to its relatively low expression levels in plant tissues. When designing experiments to study EPFL7, researchers should consider using samples from various developmental stages, as expression patterns may vary throughout the plant life cycle. The commercially available antibody against EPFL7 (such as the polyclonal antibody CSB-PA503985XA01DOA) is raised against recombinant Arabidopsis thaliana EPFL7 protein .
The EPFL7 antibody has been validated for several key applications:
ELISA (Enzyme-Linked Immunosorbent Assay): Effective for quantitative measurement of EPFL7 protein levels
Western Blot (WB): Useful for detecting the presence and relative abundance of EPFL7 in tissue samples
When planning experimental approaches, researchers should note that antibody performance may vary depending on sample preparation methods. For optimal results, follow manufacturer-recommended dilutions while also performing validation tests in your specific experimental system .
For maximum stability and longevity of your EPFL7 antibody:
Store at -20°C or -80°C upon receipt
Avoid repeated freeze-thaw cycles, which can significantly reduce antibody activity
For antibodies in liquid form, store in the recommended buffer (typically with preservatives like 0.03% Proclin 300)
Storage in 50% glycerol helps maintain antibody stability during freeze-thaw cycles when necessary
Proper experimental design requires rigorous controls:
| Control Type | Purpose | Implementation |
|---|---|---|
| Negative control | Assess non-specific binding | Sample lacking EPFL7 expression (knockout/knockdown) |
| Positive control | Confirm antibody functionality | Recombinant EPFL7 protein or known EPFL7-expressing tissue |
| Secondary antibody control | Determine background signal | Primary antibody omitted, secondary antibody only |
| Blocking peptide control | Verify specificity | Pre-incubate antibody with blocking peptide prior to use |
Implementing these controls is especially important when working with polyclonal antibodies like the EPFL7 antibody (CSB-PA503985XA01DOA), as they may show cross-reactivity with structurally similar proteins in the EPF family .
Effective sample preparation is critical for successful EPFL7 detection:
Tissue homogenization: Use liquid nitrogen grinding followed by buffer extraction
Buffer selection: For plant tissues, phosphate-buffered saline (PBS, pH 7.4) with protease inhibitors is recommended
Protein extraction: Include 0.1-1% detergent (Triton X-100 or NP-40) to solubilize membrane-associated proteins
Centrifugation: Clear lysates at 12,000-15,000 g for 10-15 minutes at 4°C
Protein quantification: Use Bradford or BCA assay to normalize protein loading
These methods help ensure consistent and reproducible results when working with EPFL7 antibodies across different experimental systems.
Non-specific binding is a common challenge when working with polyclonal antibodies. To address this issue:
Optimize blocking conditions: Test different blocking agents (5% non-fat milk, 3-5% BSA, or commercial blocking buffers)
Adjust antibody dilution: Test serial dilutions to find optimal concentration (typically 1:1000-1:4000 for Western blots)
Increase washing stringency: Use PBS-T (PBS with 0.05-0.1% Tween-20) and increase washing duration
Pre-absorb antibody: Incubate with tissues lacking EPFL7 to remove cross-reactive antibodies
Optimize incubation conditions: Test various temperatures (4°C, room temperature) and durations
For particularly challenging samples, consider using antigen retrieval methods commonly employed in immunohistochemistry to improve epitope accessibility while maintaining tissue morphology.
Successful immunolocalization of EPFL7 requires specialized techniques:
Fixation optimization: Test both aldehyde-based (4% paraformaldehyde) and alcohol-based fixatives
Embedding method selection: Paraffin embedding works well for general morphology, while cryosectioning better preserves antigenicity
Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) often improves antibody binding
Signal amplification: Consider tyramide signal amplification (TSA) to detect low-abundance EPFL7
Counterstaining: Use differential interference contrast (DIC) or fluorescent markers for cellular structures
These advanced approaches can significantly improve the sensitivity and specificity of EPFL7 detection in complex plant tissues.
For quantitative analysis of EPFL7 expression:
Quantitative Western Blot:
Use internal loading controls (actin, tubulin, or GAPDH)
Apply density-based quantification software
Generate standard curves with recombinant protein
ELISA-based quantification:
Develop sandwich ELISA with capture and detection antibodies
Use purified recombinant EPFL7 for standard curve generation
Validate with spike-in recovery experiments
Immunoprecipitation followed by mass spectrometry:
Provides absolute quantification capabilities
Allows detection of post-translational modifications
Enables identification of interaction partners
When reporting quantitative results, always include statistical analysis methods and clearly state biological versus technical replication numbers.
Fixation method selection significantly impacts antibody binding:
| Fixation Method | Advantages | Disadvantages | Best For |
|---|---|---|---|
| 4% Paraformaldehyde | Good morphology preservation | May mask some epitopes | Immunofluorescence |
| 100% Methanol | Better antigen preservation | Poorer morphology | Western blotting |
| Acetone | Minimal epitope masking | Poor structural preservation | Quick immunostaining |
| Glutaraldehyde | Excellent ultrastructure | Significant autofluorescence | Electron microscopy |
For EPFL7 detection, a combination approach using 4% paraformaldehyde followed by partial permeabilization with a low concentration of detergent often yields optimal results for balancing epitope preservation and structural integrity.
Protein-level detection using EPFL7 antibody provides several advantages over transcript analysis:
Post-transcriptional regulation: Detects actual protein levels which may not correlate with mRNA abundance
Protein localization: Enables subcellular localization studies not possible with transcript analysis
Post-translational modifications: Can detect modified forms of EPFL7 depending on antibody specificity
Protein stability assessment: Allows studies of protein turnover rates and stability
Protein-protein interactions: Facilitates co-immunoprecipitation studies to identify interaction partners
When designing comprehensive studies, combining antibody-based protein detection with transcript analysis provides the most complete picture of EPFL7 regulation and function.
Rigorous validation of antibody specificity is essential, particularly in genetically modified systems:
Genetic knockout/knockdown validation:
Test antibody in EPFL7 knockout/knockdown lines
Signal should be absent or significantly reduced
Overexpression validation:
Test in EPFL7 overexpression lines
Signal should be proportionally increased
Epitope tagging approach:
Create epitope-tagged EPFL7 constructs
Compare detection using EPFL7 antibody versus tag-specific antibody
Preabsorption test:
Preincubate antibody with purified antigen
Should eliminate specific signal while leaving non-specific binding